JP Stock MarketDetailed Quotes

4527 Rohto Pharmaceutical

Watchlist
  • 3502.0
  • -23.0-0.65%
20min DelayTrading Oct 17 14:38 JST
827.10BMarket Cap25.90P/E (Static)

Rohto Pharmaceutical Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Rohto Pharmaceutical Q2 2025 Estimates Date

Currency：JPYNov 13, 2024

Estimate YoY
Revenue
70.85B
+6.23%
EPS
35.07
+6.63%
Analyst Rating
Buy

Sep 26, 2024

Rohto Pharmaceutical Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 5 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: JPY

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q3-- / 85.296B--
Nov 13, 20242025/Q2-- / 70.851B--
Aug 7, 20242025/Q168.356B / 67.660B--
May 13, 20242024/Q469.677B / 71.304B--
Feb 9, 20242024/Q373.294B / 73.819B--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q3-- / 85.296B--
Nov 13, 20242025/Q2-- / 70.851B--
Aug 7, 20242025/Q168.356B / 67.660B--
May 13, 20242024/Q469.677B / 71.304B--
Feb 9, 20242024/Q373.294B / 73.819B--

Unlock Free Earnings Estimates

Rohto Pharmaceutical Earnings Reports

  • Rohto Pharmaceutical: Overview of consolidated financial statements for the first quarter (April 1 to June 30) of the fiscal year ending March 2025.

    Aug 7 02:00 ET

  • Rohto Pharmaceutical: Announcements of individual stocks regarding revisions in financial estimates and dividend forecasts (increase in dividends).

    Aug 7 02:00 ET

  • Rohto Pharmaceutical: Consolidated financial results for the first quarter ending March 2025 (based on Japanese standards)

    Aug 7 02:00 ET

  • Rohto Pharmaceutical: Interim report

    Jul 1 02:37 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Sep 26, 2024

    Buy

    • Strong Buy

      44.44%

    • Buy

      55.56%

    • Hold

      0.00%

    • Underperform

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    JP
    Overall
    Symbol
    Latest Price
    % Chg

    No Data